Estrogen and C-reactive protein: does an alternate route lead to a more attractive destination?

• References

• 1 Hulley S, Grady D, Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/pro-gestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
• 2 Rossouw JE, Anderson GL, Prentice RL. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
• 3 Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53: 605-19.
• 4 Ridker PM, Rifai N, Rose L. et al. Comparison of C-reactive protein and low-density lipo-protein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-65.
• 5 Lacut K, Oger E, Le Gal G. et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on c-reactive protein. Thromb Haemost 2003; 90: 124-31.
• 6 Decensi A, Omodei U, Robertson C. et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106: 1224-8.
• 7 Vongpatanasin W, Tuncel M, Wang Z. et al. Differential Effects of Oral Versus Transdermal Estrogen Replacement Therapy on C-Reactive Protein in Postmenopausal Women. J Amer Coll Cardiol 2003; 41: 1358-63.
• 8 Cherry N, Gilmour K, Hannaford P. et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360: 2001-8.
• 9 Clarke SC, Kelleher J, Lloyd-Jones H. et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002; 109: 1056-62.